SHAREHOLDER ALERT: Investigation of Intercept Announced by Holzer & Holzer, LLC

Atlanta, Georgia--(Newsfile Corp. - November 2, 2020) - Holzer & Holzer, LLC is investigating whether Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) ("Intercept" or the "Company") complied with federal securities laws. In its most recent 10-Q filed with the SEC, the Company disclosed "the FDA has notified us that in the course of its routine safety surveillance, in May 2020 the FDA began to evaluate a newly identified safety signal regarding liver disorder for Ocaliva which the FDA classified as a potential risk." The price of Intercept's stock fell following the announcement.

If you purchased shares of Intercept and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Luke R. Kennedy, Esq. at lkennedy@holzerlaw.com, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.

CONTACT:

Corey D. Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67220